Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial
This study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of 100 cancer-free patients with peripheral arterial disease (PAD) participating in the Veterans Affairs (VA) Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). FeAST, a pros...
Gespeichert in:
| Veröffentlicht in: | Journal of vascular surgery Jg. 51; H. 6; S. 1498 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.06.2010
|
| Schlagworte: | |
| ISSN: | 1097-6809, 1097-6809 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | This study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of 100 cancer-free patients with peripheral arterial disease (PAD) participating in the Veterans Affairs (VA) Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). FeAST, a prospective, randomized, single-blind clinical trial, tested the hypothesis that reduction of iron stores using phlebotomy would influence clinical outcomes in 1227 PAD patients randomized to iron reduction or control groups. The effects of statin administration were also examined in the Sierra Nevada Health Care (SNHC) cohort by measuring serum ferritin levels at entry and during the 6-year study period. No difference was documented between treatment groups in all-cause mortality and secondary outcomes of death plus nonfatal myocardial infarction and stroke. Iron reduction in the main study caused a significant age-related improvement in cardiovascular disease outcomes, new cancer diagnoses, and cancer-specific death.
Tumor necrosis factor (TNF)-alpha, TNF-alpha receptors 1 and 2, interleukin (IL)-2, IL-6, IL-10, and high-sensitivity C reactive protein (hs-CRP) were measured at entry and at 6-month intervals for 6 years. Average levels of ferritin and lipids at entry and at the end of the study were compared. The clinical course and ferritin levels of 23 participants who died during the study were reviewed.
At entry, mean age of entry was 67 +/- 9 years for the SNHCS cohort, comparable to FeAST and clinical and laboratory parameters were equivalent in substudy participants randomized to iron reduction (n = 51) or control (n = 49). At baseline, 53 participants on statins had slightly lower mean entry-level ferritin values (114.06 ng/mL; 95% confidence interval [CI] 93.43-134.69) vs the 47 off statins (127.62 ng/mL; 95% CI, 103.21-152.02). Longitudinal analysis of follow-up data, after adjusting for the phlebotomy treatment effect, showed that statin use was associated with significantly lower ferritin levels (-29.78 ng/mL; Cohen effect size, -0.47 [t(df, 134) = 2.33, P = .02]). Mean follow-up average ferritin levels were higher in 23 participants who died (132.5 ng/mL; 95% CI, 79.36-185.66) vs 77 survivors (83.6 ng/mL; 95% CI, 70.34-96.90; Wilcoxon P = .05). Mean follow-up IL-6 levels were higher in dead participants (21.68 ng/mL; 95% CI, 13.71-29.66) vs survivors (12.61 ng/mL; 95% CI, 10.72-14.50; Wilcoxon P = .018). Ferritin levels correlated (Pearson) with average IL-6 levels (r = 0.1845; P = .002) and hsCRP levels (r = .1175; P = .04) during the study.
These data demonstrate statistical correlations between levels of ferritin, inflammatory biomarkers, and mortality in this subset of patients with PAD. |
|---|---|
| AbstractList | This study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of 100 cancer-free patients with peripheral arterial disease (PAD) participating in the Veterans Affairs (VA) Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). FeAST, a prospective, randomized, single-blind clinical trial, tested the hypothesis that reduction of iron stores using phlebotomy would influence clinical outcomes in 1227 PAD patients randomized to iron reduction or control groups. The effects of statin administration were also examined in the Sierra Nevada Health Care (SNHC) cohort by measuring serum ferritin levels at entry and during the 6-year study period. No difference was documented between treatment groups in all-cause mortality and secondary outcomes of death plus nonfatal myocardial infarction and stroke. Iron reduction in the main study caused a significant age-related improvement in cardiovascular disease outcomes, new cancer diagnoses, and cancer-specific death.
Tumor necrosis factor (TNF)-alpha, TNF-alpha receptors 1 and 2, interleukin (IL)-2, IL-6, IL-10, and high-sensitivity C reactive protein (hs-CRP) were measured at entry and at 6-month intervals for 6 years. Average levels of ferritin and lipids at entry and at the end of the study were compared. The clinical course and ferritin levels of 23 participants who died during the study were reviewed.
At entry, mean age of entry was 67 +/- 9 years for the SNHCS cohort, comparable to FeAST and clinical and laboratory parameters were equivalent in substudy participants randomized to iron reduction (n = 51) or control (n = 49). At baseline, 53 participants on statins had slightly lower mean entry-level ferritin values (114.06 ng/mL; 95% confidence interval [CI] 93.43-134.69) vs the 47 off statins (127.62 ng/mL; 95% CI, 103.21-152.02). Longitudinal analysis of follow-up data, after adjusting for the phlebotomy treatment effect, showed that statin use was associated with significantly lower ferritin levels (-29.78 ng/mL; Cohen effect size, -0.47 [t(df, 134) = 2.33, P = .02]). Mean follow-up average ferritin levels were higher in 23 participants who died (132.5 ng/mL; 95% CI, 79.36-185.66) vs 77 survivors (83.6 ng/mL; 95% CI, 70.34-96.90; Wilcoxon P = .05). Mean follow-up IL-6 levels were higher in dead participants (21.68 ng/mL; 95% CI, 13.71-29.66) vs survivors (12.61 ng/mL; 95% CI, 10.72-14.50; Wilcoxon P = .018). Ferritin levels correlated (Pearson) with average IL-6 levels (r = 0.1845; P = .002) and hsCRP levels (r = .1175; P = .04) during the study.
These data demonstrate statistical correlations between levels of ferritin, inflammatory biomarkers, and mortality in this subset of patients with PAD. This study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of 100 cancer-free patients with peripheral arterial disease (PAD) participating in the Veterans Affairs (VA) Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). FeAST, a prospective, randomized, single-blind clinical trial, tested the hypothesis that reduction of iron stores using phlebotomy would influence clinical outcomes in 1227 PAD patients randomized to iron reduction or control groups. The effects of statin administration were also examined in the Sierra Nevada Health Care (SNHC) cohort by measuring serum ferritin levels at entry and during the 6-year study period. No difference was documented between treatment groups in all-cause mortality and secondary outcomes of death plus nonfatal myocardial infarction and stroke. Iron reduction in the main study caused a significant age-related improvement in cardiovascular disease outcomes, new cancer diagnoses, and cancer-specific death.BACKGROUNDThis study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of 100 cancer-free patients with peripheral arterial disease (PAD) participating in the Veterans Affairs (VA) Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). FeAST, a prospective, randomized, single-blind clinical trial, tested the hypothesis that reduction of iron stores using phlebotomy would influence clinical outcomes in 1227 PAD patients randomized to iron reduction or control groups. The effects of statin administration were also examined in the Sierra Nevada Health Care (SNHC) cohort by measuring serum ferritin levels at entry and during the 6-year study period. No difference was documented between treatment groups in all-cause mortality and secondary outcomes of death plus nonfatal myocardial infarction and stroke. Iron reduction in the main study caused a significant age-related improvement in cardiovascular disease outcomes, new cancer diagnoses, and cancer-specific death.Tumor necrosis factor (TNF)-alpha, TNF-alpha receptors 1 and 2, interleukin (IL)-2, IL-6, IL-10, and high-sensitivity C reactive protein (hs-CRP) were measured at entry and at 6-month intervals for 6 years. Average levels of ferritin and lipids at entry and at the end of the study were compared. The clinical course and ferritin levels of 23 participants who died during the study were reviewed.METHODSTumor necrosis factor (TNF)-alpha, TNF-alpha receptors 1 and 2, interleukin (IL)-2, IL-6, IL-10, and high-sensitivity C reactive protein (hs-CRP) were measured at entry and at 6-month intervals for 6 years. Average levels of ferritin and lipids at entry and at the end of the study were compared. The clinical course and ferritin levels of 23 participants who died during the study were reviewed.At entry, mean age of entry was 67 +/- 9 years for the SNHCS cohort, comparable to FeAST and clinical and laboratory parameters were equivalent in substudy participants randomized to iron reduction (n = 51) or control (n = 49). At baseline, 53 participants on statins had slightly lower mean entry-level ferritin values (114.06 ng/mL; 95% confidence interval [CI] 93.43-134.69) vs the 47 off statins (127.62 ng/mL; 95% CI, 103.21-152.02). Longitudinal analysis of follow-up data, after adjusting for the phlebotomy treatment effect, showed that statin use was associated with significantly lower ferritin levels (-29.78 ng/mL; Cohen effect size, -0.47 [t(df, 134) = 2.33, P = .02]). Mean follow-up average ferritin levels were higher in 23 participants who died (132.5 ng/mL; 95% CI, 79.36-185.66) vs 77 survivors (83.6 ng/mL; 95% CI, 70.34-96.90; Wilcoxon P = .05). Mean follow-up IL-6 levels were higher in dead participants (21.68 ng/mL; 95% CI, 13.71-29.66) vs survivors (12.61 ng/mL; 95% CI, 10.72-14.50; Wilcoxon P = .018). Ferritin levels correlated (Pearson) with average IL-6 levels (r = 0.1845; P = .002) and hsCRP levels (r = .1175; P = .04) during the study.RESULTSAt entry, mean age of entry was 67 +/- 9 years for the SNHCS cohort, comparable to FeAST and clinical and laboratory parameters were equivalent in substudy participants randomized to iron reduction (n = 51) or control (n = 49). At baseline, 53 participants on statins had slightly lower mean entry-level ferritin values (114.06 ng/mL; 95% confidence interval [CI] 93.43-134.69) vs the 47 off statins (127.62 ng/mL; 95% CI, 103.21-152.02). Longitudinal analysis of follow-up data, after adjusting for the phlebotomy treatment effect, showed that statin use was associated with significantly lower ferritin levels (-29.78 ng/mL; Cohen effect size, -0.47 [t(df, 134) = 2.33, P = .02]). Mean follow-up average ferritin levels were higher in 23 participants who died (132.5 ng/mL; 95% CI, 79.36-185.66) vs 77 survivors (83.6 ng/mL; 95% CI, 70.34-96.90; Wilcoxon P = .05). Mean follow-up IL-6 levels were higher in dead participants (21.68 ng/mL; 95% CI, 13.71-29.66) vs survivors (12.61 ng/mL; 95% CI, 10.72-14.50; Wilcoxon P = .018). Ferritin levels correlated (Pearson) with average IL-6 levels (r = 0.1845; P = .002) and hsCRP levels (r = .1175; P = .04) during the study.These data demonstrate statistical correlations between levels of ferritin, inflammatory biomarkers, and mortality in this subset of patients with PAD.CONCLUSIONThese data demonstrate statistical correlations between levels of ferritin, inflammatory biomarkers, and mortality in this subset of patients with PAD. |
| Author | Zacharski, Leo R May, Patricia E Hayes, Virginia W Depalma, Ralph G Shamayeva, Galina Chow, Bruce K |
| Author_xml | – sequence: 1 givenname: Ralph G surname: Depalma fullname: Depalma, Ralph G email: ralph.depalma@va.gov organization: Department of Veterans Affairs, Washington, DC, USA. ralph.depalma@va.gov – sequence: 2 givenname: Virginia W surname: Hayes fullname: Hayes, Virginia W – sequence: 3 givenname: Bruce K surname: Chow fullname: Chow, Bruce K – sequence: 4 givenname: Galina surname: Shamayeva fullname: Shamayeva, Galina – sequence: 5 givenname: Patricia E surname: May fullname: May, Patricia E – sequence: 6 givenname: Leo R surname: Zacharski fullname: Zacharski, Leo R |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20304584$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1KAzEUhYNUbK0-gBvJTgVnvJnfjLtSrAqCC-u6JDN3MDUzqUmm0GfxZY1awc39OefjLM4xGfWmR0LOGMQMWHGzjtdbFycAVcySGAp-QCYMqjIqOFSjf_eYHDu3BmAs5-URGSeQQpbzbEI-F2it8qqnGreo3TVVfatF1wlv7I5KZTph39EGQ_QN7Yz1Qiu_CxjdoFWbN7RCU2F9eMLRKIfC4S0V1A3S-aHZUdNS_4b00ZqeXi7w6idpFiRrXK2_p3L05QcN9uxleUWX32En5LAV2uHpfk_J6-JuOX-Inp7vH-ezp6jOeOmjKs9zaGvI66pijZSYIkqW5QiFaAWvAZloMYWSB5mBbKVkMoei4SWvywSTKbn4zd1Y8zGg86tOuRq1Fj2awa3KNGWMp6wI5PmeHGSHzWpjVahnt_rrM_kCAKt8uQ |
| CitedBy_id | crossref_primary_10_1039_C3MT00347G crossref_primary_10_1177_0267659113505637 crossref_primary_10_1177_1538574412456304 crossref_primary_10_3945_ajcn_111_015115 crossref_primary_10_1007_s10534_011_9415_8 crossref_primary_10_1016_j_jvs_2015_09_018 crossref_primary_10_1016_j_cyto_2015_12_023 crossref_primary_10_1016_j_nurpra_2011_05_001 crossref_primary_10_1007_s12170_011_0185_1 crossref_primary_10_1007_s10157_014_1074_y crossref_primary_10_3390_biom8030043 crossref_primary_10_1161_STROKEAHA_110_596510 crossref_primary_10_1161_STROKEAHA_112_679662 crossref_primary_10_1177_2050640619891283 crossref_primary_10_1161_ATVBAHA_120_314774 crossref_primary_10_1089_ars_2020_8167 crossref_primary_10_1371_journal_pone_0147990 crossref_primary_10_3109_01913123_2011_627491 crossref_primary_10_2105_AJPH_2012_301163 crossref_primary_10_1093_qjmed_hcs204 crossref_primary_10_1371_journal_pone_0048645 crossref_primary_10_3390_biom13111640 crossref_primary_10_1016_j_jvs_2011_09_004 crossref_primary_10_3390_biom11050613 crossref_primary_10_1016_j_ejvs_2017_05_009 crossref_primary_10_1186_1471_2369_13_100 crossref_primary_10_1155_2022_7647431 crossref_primary_10_1093_mtomcs_mfab030 crossref_primary_10_3390_metabo12010054 crossref_primary_10_1371_journal_pone_0085271 crossref_primary_10_3389_fphar_2014_00094 crossref_primary_10_1016_j_pharmthera_2021_107992 crossref_primary_10_1038_ejcn_2010_252 crossref_primary_10_1016_j_jvs_2012_12_077 crossref_primary_10_1373_clinchem_2014_231266 crossref_primary_10_3390_nu5072384 crossref_primary_10_3892_ijmm_2014_1657 crossref_primary_10_1016_j_jvs_2010_04_052 crossref_primary_10_1016_S1665_2681_19_30923_8 crossref_primary_10_1016_j_atherosclerosis_2025_119111 crossref_primary_10_3748_wjg_v22_i29_6742 crossref_primary_10_1155_2020_4138696 crossref_primary_10_1161_STROKEAHA_117_018724 crossref_primary_10_1016_j_amjcard_2019_07_056 crossref_primary_10_1016_j_diabres_2014_08_022 crossref_primary_10_3390_jcm12206547 crossref_primary_10_1016_j_jand_2018_09_007 crossref_primary_10_1007_s00125_020_05153_0 crossref_primary_10_1161_STROKEAHA_112_663286 crossref_primary_10_1016_j_ijcard_2013_12_176 crossref_primary_10_1177_1708538113478776 crossref_primary_10_3390_cimb46090564 crossref_primary_10_3945_an_113_003681 crossref_primary_10_1007_s00204_010_0577_x crossref_primary_10_1097_gme_0b013e318287b888 crossref_primary_10_1373_clinchem_2014_229013 crossref_primary_10_1039_c4ib00173g crossref_primary_10_52711_0974_360X_2024_00648 crossref_primary_10_1111_j_1537_2995_2011_03062_x crossref_primary_10_3945_ajcn_112_040774 crossref_primary_10_3390_jcm11175251 crossref_primary_10_1039_C4IB00025K crossref_primary_10_1111_j_1537_2995_2011_03488_x |
| ContentType | Journal Article |
| Copyright | Published by Mosby, Inc. |
| Copyright_xml | – notice: Published by Mosby, Inc. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jvs.2009.12.068 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-6809 |
| ExternalDocumentID | 20304584 |
| Genre | Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S Journal Article |
| GroupedDBID | --- --K .1- .55 .FO .GJ .XZ 0R~ 1B1 1P~ 1~5 2WC 354 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AAIKJ AALRI AAQFI AAQXK AAXUO AAYWO ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACPHU ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AENEX AEUPX AEVXI AEXQZ AFCTW AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGHFR AGQPQ AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BELOY C45 C5W CAG CGR COF CS3 CUY CVF DIK DU5 E3Z EBS ECM EFJIC EFKBS EIF EJD FDB FEDTE FGOYB FRP GBLVA HVGLF HZ~ IHE IXB J1W J5H K-O KOM L7B M41 MO0 N4W NPM NQ- O-L O9- OB2 OBH OHH OK- OK1 OVD OW- OZT P2P R2- RIG ROL RPZ SDG SDP SEL SES SEW SJN SSZ TEORI UHS UV1 VVN W2D X7M XH2 YFH YOC Z5R ZGI ZXP ZY1 7X8 |
| ID | FETCH-LOGICAL-c487t-95550fc05c991dbbe3eeb145e06afa8c0e1afe3078eb110bfbb1b506d878c72e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 77 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000277974200023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1097-6809 |
| IngestDate | Sun Sep 28 12:05:34 EDT 2025 Mon Jul 21 05:49:16 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Published by Mosby, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c487t-95550fc05c991dbbe3eeb145e06afa8c0e1afe3078eb110bfbb1b506d878c72e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.jvs.2009.12.068 |
| PMID | 20304584 |
| PQID | 733118316 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_733118316 pubmed_primary_20304584 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-06-01 |
| PublicationDateYYYYMMDD | 2010-06-01 |
| PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of vascular surgery |
| PublicationTitleAlternate | J Vasc Surg |
| PublicationYear | 2010 |
| References | 20670792 - J Vasc Surg. 2010 Aug;52(2):536-7; author reply 537 |
| References_xml | – reference: 20670792 - J Vasc Surg. 2010 Aug;52(2):536-7; author reply 537 |
| SSID | ssj0011587 |
| Score | 2.3110209 |
| Snippet | This study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of 100 cancer-free patients with peripheral arterial... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1498 |
| SubjectTerms | Aged Aged, 80 and over Atherosclerosis - blood Atherosclerosis - mortality Atherosclerosis - therapy Biomarkers - blood C-Reactive Protein - metabolism Ferritins - blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Inflammation Mediators - blood Interleukin-10 - blood Interleukin-2 - blood Interleukin-6 - blood Iron - blood Kaplan-Meier Estimate Middle Aged Peripheral Vascular Diseases - blood Peripheral Vascular Diseases - mortality Peripheral Vascular Diseases - therapy Phlebotomy Proportional Hazards Models Prospective Studies Receptors, Tumor Necrosis Factor, Type I - blood Receptors, Tumor Necrosis Factor, Type II - blood Risk Assessment Risk Factors Single-Blind Method Time Factors Treatment Outcome Tumor Necrosis Factor-alpha - blood |
| Title | Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20304584 https://www.proquest.com/docview/733118316 |
| Volume | 51 |
| WOSCitedRecordID | wos000277974200023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeuoGBSkTk0SQuC6oQFQytKrVI3SLbsaWiNilN6Z_hz3LnpDAhBhYPsWNZzvny3X3nO8au6XKnlIo7wg9CNFCkcoT0AsdX2qDxo4U03BabiHs9Phq1-lVsTlGFVa50olXUaa7IR35HtQVR_LzoYfbuUNEoIlerChrrrBYgkiGhjkc_JIIX2vp4xLE6EXdbK1LThne9LYsyWyU5AyP-O8C0P5rO7j-XuMd2KoQJ7VIk9tmazg7YVrfi0A_ZZ4eSMS7GGUwoYKi4BRQylIup5duB7uNTyM4cO0SWwtTic8TqOAwoLbLNQzABGwuKwgsVxXMPAgrUQpSuFnIDCCzhZZ5ncNPRDTtTm7BmXuCisB0XMLBDsbs9GDZgSJMdsdfO0_Dx2alKNDgKLZ2F0wrRwjHKDRXizFRKHWhU_s1Qu5EwgitXe8Jo1CMcH3uuNFJ6MnSjlMdcxb72j9lGlmf6lEFqpBsZHMdV1NR-2kJdaoRWgecb6TdlncFq1xM8AsRriEznH0Xyve91dlJ-uWRWpupI_IoJPvv75XO2XUYGkIflgtUMHn99yTbVcjEu5ldWtLDt9btfnkvcVw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ferritin+levels%2C+inflammatory+biomarkers%2C+and+mortality+in+peripheral+arterial+disease%3A+a+substudy+of+the+Iron+%28Fe%29+and+Atherosclerosis+Study+%28FeAST%29+Trial&rft.jtitle=Journal+of+vascular+surgery&rft.au=Depalma%2C+Ralph+G&rft.au=Hayes%2C+Virginia+W&rft.au=Chow%2C+Bruce+K&rft.au=Shamayeva%2C+Galina&rft.date=2010-06-01&rft.issn=1097-6809&rft.eissn=1097-6809&rft.volume=51&rft.issue=6&rft.spage=1498&rft_id=info:doi/10.1016%2Fj.jvs.2009.12.068&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1097-6809&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1097-6809&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1097-6809&client=summon |